These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 12920410

  • 21. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People.
    Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, Amminger GP, McGregor IS.
    J Clin Psychopharmacol; ; 41(5):525-533. PubMed ID: 34121064
    [Abstract] [Full Text] [Related]

  • 22. Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers.
    Wong SL, Locke C, Staser J, Granneman GR.
    Psychopharmacology (Berl); 1998 Feb; 135(3):236-41. PubMed ID: 9498726
    [Abstract] [Full Text] [Related]

  • 23. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA.
    Am J Cardiol; 2004 Nov 01; 94(9):1140-6. PubMed ID: 15518608
    [Abstract] [Full Text] [Related]

  • 24. Lack of interaction between citalopram and the CYP3A4 substrate triazolam.
    Nolting A, Abramowitz W.
    Pharmacotherapy; 2000 Jul 01; 20(7):750-5. PubMed ID: 10907965
    [Abstract] [Full Text] [Related]

  • 25. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications.
    Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI.
    J Clin Psychiatry; 1993 Oct 01; 54 Suppl():4-11; discussion 12-4. PubMed ID: 8262889
    [Abstract] [Full Text] [Related]

  • 26. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
    DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L.
    J Clin Psychopharmacol; 2004 Feb 01; 24(1):4-10. PubMed ID: 14709940
    [Abstract] [Full Text] [Related]

  • 27. Cytochrome P450 (CYP) inhibition screening: comparison of three tests.
    Turpeinen M, Korhonen LE, Tolonen A, Uusitalo J, Juvonen R, Raunio H, Pelkonen O.
    Eur J Pharm Sci; 2006 Oct 01; 29(2):130-8. PubMed ID: 16890411
    [Abstract] [Full Text] [Related]

  • 28. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK.
    Drug Metab Dispos; 2007 Jan 01; 35(1):79-85. PubMed ID: 17020957
    [Abstract] [Full Text] [Related]

  • 29. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
    McGinnity DF, Berry AJ, Kenny JR, Grime K, Riley RJ.
    Drug Metab Dispos; 2006 Aug 01; 34(8):1291-300. PubMed ID: 16679385
    [Abstract] [Full Text] [Related]

  • 30. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL, Mulder RT, Joyce PR, Luty SE, Kennedy MA.
    Hum Psychopharmacol; 2004 Jan 01; 19(1):17-23. PubMed ID: 14716707
    [Abstract] [Full Text] [Related]

  • 31. Absence of food effect on the extent of alprazolam absorption from an orally disintegrating tablet.
    Erdman K, Stypinski D, Combs M, Witt P, Stiles M, Pollock S.
    Pharmacotherapy; 2007 Aug 01; 27(8):1120-4. PubMed ID: 17655512
    [Abstract] [Full Text] [Related]

  • 32. Citalopram neuropharmacological challenge in alcohol-dependent patients and controls: pharmacogenetic, endocrine and psychobehavioral results.
    Wong WM, Hasemann S, Schwarz M, Zill P, Koller G, Soyka M, Preuss UW.
    Pharmacopsychiatry; 2008 Mar 01; 41(2):72-8. PubMed ID: 18311688
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.
    Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ.
    Psychopharmacology (Berl); 1991 Mar 01; 104(3):323-7. PubMed ID: 1924640
    [Abstract] [Full Text] [Related]

  • 34. Risk and predictability of drug interactions in the elderly.
    Levy RH, Collins C.
    Int Rev Neurobiol; 2007 Mar 01; 81():235-51. PubMed ID: 17433928
    [Abstract] [Full Text] [Related]

  • 35. Fluoxetine impairs clearance of alprazolam but not of clonazepam.
    Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS.
    Clin Pharmacol Ther; 1992 Nov 01; 52(5):479-86. PubMed ID: 1424422
    [Abstract] [Full Text] [Related]

  • 36. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM.
    J Pharmacol Exp Ther; 2006 Jan 01; 316(1):336-48. PubMed ID: 16192315
    [Abstract] [Full Text] [Related]

  • 37. Second-generation antidepressants.
    Rudorfer MV, Golden RN, Potter WZ.
    Psychiatr Clin North Am; 1984 Sep 01; 7(3):519-34. PubMed ID: 6237317
    [Abstract] [Full Text] [Related]

  • 38. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
    Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C.
    J Clin Pharmacol; 2007 Feb 01; 47(2):146-58. PubMed ID: 17244765
    [Abstract] [Full Text] [Related]

  • 39. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine.
    Burghardt NS, Sullivan GM, McEwen BS, Gorman JM, LeDoux JE.
    Biol Psychiatry; 2004 Jun 15; 55(12):1171-8. PubMed ID: 15184036
    [Abstract] [Full Text] [Related]

  • 40. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
    Lu C, Hatsis P, Berg C, Lee FW, Balani SK.
    Drug Metab Dispos; 2008 Jul 15; 36(7):1255-60. PubMed ID: 18381489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.